A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer
G Giaccone, T Lechevalier, N Thatcher… - Journal of Clinical …, 2005 - ascopubs.org
7073 Background: Erlotinib (TarcevaTM) is an orally available selective EGFR tyrosine-
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …
kinase inhibitor. In patients with advanced NSCLC, 2nd/3rd-line erlotinib significantly …
Erlotinib: Small-molecule targeted therapy in the treatmentof non-small-cell lung cancer
J Smith - Clinical therapeutics, 2005 - Elsevier
BACKGROUND:: Erlotinib is an oral tyrosine kinase inhibitor, 1026 targeting the human
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
epidermal receptor type 1/epidermal growth factor receptor, recently approved by the US …
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …
FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
[HTML][HTML] Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib
Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …
Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status …
R Lilenbaum, R Axerold, S Thomas… - Journal of Clinical …, 2006 - ascopubs.org
7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …
[HTML][HTML] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
M Ranson, M Reck, A Anthoney, AR Hanauske… - Annals of oncology, 2010 - Elsevier
Background Erlotinib and pemetrexed are approved single agents for second-line treatment
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
of non-small-cell lung cancer (NSCLC) and, in combination, have shown synergistic …
Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: a meta‐analysis
Gefitinib, erlotinib and afatinib are three widely used epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
tyrosine kinase inhibitors (EGFR TKIs) for treating advanced non‐small cell lung cancer …
[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib …
N Reguart, R Rosell, F Cardenal, AF Cardona, D Isla… - Lung cancer, 2014 - Elsevier
Objectives Vorinostat or suberoylanilide hydroxamic acid (SAHA) is a novel histone
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …
deacetylase inhibitor with demonstrated antiproliferative effects due to drug-induced …
Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas… - The lancet …, 2010 - thelancet.com
Background First-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) is
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …
usually limited to four to six cycles. Maintenance therapy can delay progression and prolong …